Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001628280-18-003200
Filing Date
2018-03-15
Accepted
2018-03-14 17:45:34
Documents
6
Period of Report
2018-04-24
Effectiveness Date
2018-03-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A 2018 PROXY STATEMENT a2018proxystatement.htm DEF 14A 674316
2 ajbackgroundpicture.jpg GRAPHIC 10605
3 cumberlandlogoa02a01.jpg GRAPHIC 12534
4 cumberlandpharmalogoa01.jpg GRAPHIC 37721
5 untitleda01a01.jpg GRAPHIC 9167
6 xa01.jpg GRAPHIC 2405
  Complete submission text file 0001628280-18-003200.txt   775718
Mailing Address 2525 WEST END AVENUE SUITE 950 NASHVILLE TN 37203
Business Address 2525 WEST END AVENUE SUITE 950 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 000000000
Type: DEF 14A | Act: 34 | File No.: 001-33637 | Film No.: 18690465
SIC: 2834 Pharmaceutical Preparations